LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...
A 40-year-old woman with type 1 diabetes mellitus (T1DM) who injected insulin into her abdomen developed a firm subcutaneous mass in the right lower quadrant. Pathology after surgical excision showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results